- Home
- ADEA vs BEAM Comparison
ADEA vs BEAM Comparison
Compare ADEA & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADEA
- BEAM
- Stock Information
- Founded
- ADEA 1990
- BEAM 2017
- Country
- ADEA United States
- BEAM United States
- Employees
- ADEA N/A
- BEAM N/A
- Industry
- ADEA Computer Software: Prepackaged Software
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADEA Technology
- BEAM Health Care
- Exchange
- ADEA Nasdaq
- BEAM Nasdaq
- Market Cap
- ADEA 1.6B
- BEAM 1.7B
- IPO Year
- ADEA N/A
- BEAM 2020
- Fundamental
- Price
- ADEA $15.52
- BEAM $16.64
- Analyst Decision
- ADEA Strong Buy
- BEAM Strong Buy
- Analyst Count
- ADEA 4
- BEAM 10
- Target Price
- ADEA $19.50
- BEAM $48.56
- AVG Volume (30 Days)
- ADEA 551.8K
- BEAM 2.5M
- Earning Date
- ADEA 08-05-2025
- BEAM 08-05-2025
- Dividend Yield
- ADEA 1.37%
- BEAM N/A
- EPS Growth
- ADEA 80.44
- BEAM N/A
- EPS
- ADEA 0.74
- BEAM N/A
- Revenue
- ADEA $378,674,000.00
- BEAM $60,272,000.00
- Revenue This Year
- ADEA $10.01
- BEAM N/A
- Revenue Next Year
- ADEA $4.42
- BEAM $17.18
- P/E Ratio
- ADEA $20.98
- BEAM N/A
- Revenue Growth
- ADEA 5.47
- BEAM N/A
- 52 Week Low
- ADEA $10.59
- BEAM $13.53
- 52 Week High
- ADEA $17.46
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- ADEA 66.17
- BEAM 38.79
- Support Level
- ADEA $14.40
- BEAM $15.60
- Resistance Level
- ADEA $15.39
- BEAM $18.17
- Average True Range (ATR)
- ADEA 0.58
- BEAM 0.93
- MACD
- ADEA 0.13
- BEAM -0.20
- Stochastic Oscillator
- ADEA 95.29
- BEAM 29.89
About ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.